These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
199 related articles for article (PubMed ID: 9150467)
1. Interaction between beta 2-microglobulin and advanced glycation end products in the development of dialysis related-amyloidosis. Hou FF; Chertow GM; Kay J; Boyce J; Lazarus JM; Braatz JA; Owen WF Kidney Int; 1997 May; 51(5):1514-9. PubMed ID: 9150467 [TBL] [Abstract][Full Text] [Related]
2. Beta 2-microglobulin modified with advanced glycation end products modulates collagen synthesis by human fibroblasts. Owen WF; Hou FF; Stuart RO; Kay J; Boyce J; Chertow GM; Schmidt AM Kidney Int; 1998 May; 53(5):1365-73. PubMed ID: 9573554 [TBL] [Abstract][Full Text] [Related]
3. Modification of beta 2m with advanced glycation end products as observed in dialysis-related amyloidosis by 3-DG accumulating in uremic serum. Niwa T; Katsuzaki T; Momoi T; Miyazaki T; Ogawa H; Saito A; Miyazaki S; Maeda K; Tatemichi N; Takei Y Kidney Int; 1996 Mar; 49(3):861-7. PubMed ID: 8648931 [TBL] [Abstract][Full Text] [Related]
4. Amyloid beta 2-microglobulin is modified with imidazolone, a novel advanced glycation end product, in dialysis-related amyloidosis. Niwa T; Katsuzaki T; Miyazaki S; Momoi T; Akiba T; Miyazaki T; Nokura K; Hayase F; Tatemichi N; Takei Y Kidney Int; 1997 Jan; 51(1):187-94. PubMed ID: 8995733 [TBL] [Abstract][Full Text] [Related]
5. Monocyte/macrophage response to beta 2-microglobulin modified with advanced glycation end products. Miyata T; Iida Y; Ueda Y; Shinzato T; Seo H; Monnier VM; Maeda K; Wada Y Kidney Int; 1996 Feb; 49(2):538-50. PubMed ID: 8821842 [TBL] [Abstract][Full Text] [Related]
6. Involvement of beta 2-microglobulin modified with advanced glycation end products in the pathogenesis of hemodialysis-associated amyloidosis. Induction of human monocyte chemotaxis and macrophage secretion of tumor necrosis factor-alpha and interleukin-1. Miyata T; Inagi R; Iida Y; Sato M; Yamada N; Oda O; Maeda K; Seo H J Clin Invest; 1994 Feb; 93(2):521-8. PubMed ID: 8113390 [TBL] [Abstract][Full Text] [Related]
7. Extraskeletal problems and amyloid. Drüeke TB Kidney Int Suppl; 1999 Dec; 73():S89-93. PubMed ID: 10633472 [TBL] [Abstract][Full Text] [Related]
8. Beta 2-microglobulin modified with advanced glycation end products induces interleukin-6 from human macrophages: role in the pathogenesis of hemodialysis-associated amyloidosis. Iida Y; Miyata T; Inagi R; Sugiyama S; Maeda K Biochem Biophys Res Commun; 1994 Jun; 201(3):1235-41. PubMed ID: 8024566 [TBL] [Abstract][Full Text] [Related]
9. Identification of pentosidine as a native structure for advanced glycation end products in beta-2-microglobulin-containing amyloid fibrils in patients with dialysis-related amyloidosis. Miyata T; Taneda S; Kawai R; Ueda Y; Horiuchi S; Hara M; Maeda K; Monnier VM Proc Natl Acad Sci U S A; 1996 Mar; 93(6):2353-8. PubMed ID: 8637877 [TBL] [Abstract][Full Text] [Related]
10. New aspects in the pathogenesis of dialysis-related amyloidosis: pathophysiology of advanced glycation end products in renal failure. Miyata T Nihon Jinzo Gakkai Shi; 1996 May; 38(5):191-7. PubMed ID: 8699608 [TBL] [Abstract][Full Text] [Related]
11. Beta 2-microglobulin modified with the AGE products of the Maillard reaction in dialysis-related amyloidosis. Miyata T; Wada Y; Maeda K Contrib Nephrol; 1995; 112():52-64. PubMed ID: 7554993 [No Abstract] [Full Text] [Related]
13. beta 2-Microglobulin modified with advanced glycation end products is a major component of hemodialysis-associated amyloidosis. Miyata T; Oda O; Inagi R; Iida Y; Araki N; Yamada N; Horiuchi S; Taniguchi N; Maeda K; Kinoshita T J Clin Invest; 1993 Sep; 92(3):1243-52. PubMed ID: 8376584 [TBL] [Abstract][Full Text] [Related]
14. Diagnosis, pathogenesis, and treatment of dialysis-related amyloidosis. Miyata T; Inagi R; Kurokawa K Miner Electrolyte Metab; 1999; 25(1-2):114-7. PubMed ID: 10207272 [TBL] [Abstract][Full Text] [Related]
15. New aspects in the pathogenesis of dialysis-related amyloidosis: role of beta 2-microglobulin modified with advanced glycation end products in bone and joint destruction. Miyata T; Maeda K Nephrol Dial Transplant; 1996; 11 Suppl 2():140-3. PubMed ID: 8804015 [No Abstract] [Full Text] [Related]
16. Detection and quantitation of beta-2-microglobulin glycosylated end products in human serum by matrix-assisted laser desorption/ionization mass spectrometry. Tang X; Sadeghi M; Olumee Z; Vertes A; Braatz JA; McIlwain LK; Dreifuss PA Anal Chem; 1996 Nov; 68(21):3740-5. PubMed ID: 8914482 [TBL] [Abstract][Full Text] [Related]
17. Ultrastructural localization of advanced glycation end products and beta2-microglobulin in dialysis amyloidosis. Brancaccio D; Gallieni M; Niwa T; Braidotti P; Coggi G J Nephrol; 2000; 13(2):129-36. PubMed ID: 10858976 [TBL] [Abstract][Full Text] [Related]
18. Beta2-microglobulin and renal bone disease. Wada T; Miyata T; Sakai H; Kurokawa K Perit Dial Int; 1999; 19 Suppl 2():S413-6. PubMed ID: 10406556 [TBL] [Abstract][Full Text] [Related]
19. Advanced glycation of beta 2-microglobulin in the pathogenesis of bone lesions in dialysis-associated amyloidosis. Miyata T; Sprague SM Nephrol Dial Transplant; 1996; 11 Suppl 3():86-90. PubMed ID: 8840320 [No Abstract] [Full Text] [Related]